Higher Long-Term Risk of VTE in Breast Cancer Patients Confirmed

Article

Venous thromboembolism is significantly more likely over the long term in breast cancer patients than in the general population, according to a study in Sweden.

Venous thromboembolism (VTE) is significantly more likely over the long term in breast cancer patients than in the general population, according to a study in Sweden. A number of factors raise one’s risk, including cancer-specific factors such as larger tumor size, progesterone receptor status, and others.

“Although the absolute risk of VTE is relatively low for breast cancer patients in comparison with other cancer populations, the long-term consequences in terms of morbidity and quality of life are substantial,” wrote study authors led by Judith S. Brand, PhD, of Karolinska Institutet in Stockholm. Also, because breast cancer is among the world’s most common malignancies, related VTE cases contribute much to healthcare costs.

Few studies have examined the independent contributions of tumor, treatment, and other patient-related factors to the risk of VTE. The new study included 8,338 breast cancer patients in Sweden, and compared them with 39,013 age-matched reference individuals from the general population. The results were published online ahead of print in Cancer.

A total of 426 breast cancer patients experienced a VTE during a median follow-up period of 7.2 years. These patients were younger at the time of VTE diagnosis (62 years) than those in the general population (65.3 years). The breast cancer patients had a hazard ratio (HR) for VTE compared with the general population of 3.28 (95% CI, 2.87–3.74).

This relative risk was highest early on, in the first 6 months after breast cancer diagnosis (HR, 8.62 [95% CI, 6.56–11.33]), and remained high at 12 months (HR, 4.46 [95% CI, 3.52–5.66]). It remained largely constant at time points beyond that, with an HR at 2 years of 2.01 (95% CI, 1.50–2.70) and at 7 years of 2.26 (95% CI, 1.70–2.99).

A number of factors were significant predictors of VTE on a multivariate analysis. For example, tumor size > 40 mm yielded a 1.55-fold risk compared to tumors 10 mm or below in size (95% CI, 1.02–2.35). Progesterone receptor (PR)-negative patients had an HR of 1.33 (95% CI, 1.03–1.71) for VTE compared with PR-positive patients. Pre-existing VTE, older age, comorbid disease, receipt of chemotherapy and endocrine therapy, and having more than four affected lymph nodes also raised the VTE risk.

The authors noted that thromboprophylaxis can lead to a reduction in VTE incidence, but it is not generally recommended in breast cancer patients because of side effects and a low baseline risk. “Selected high-risk patients, however, could potentially benefit from prophylactic or early detection measures,” they wrote. Though there are some VTE risk prediction models available, they noted that further study is still needed to assess the added value of some laboratory parameters as well as the risk factors found in this study.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content